3 results
Primary* To characterize the dynamics of viral clearance (incl. viral cultures, qPCR, antigen clearance) following ensovibep administration * To characterize the serum pharmacokinetics of two single i.v. flat dose levels of ensovibep in patients…
To characterize the PK of eltrombopag at steady state after oral administration in pediatric patients with SAA.Secondary (key only, see protocol page 40-41 for all objectives): Safety and tolerability. Efficacy (overall response rate ORR).
Primary:• To evaluate the ability of relugolix to achieve and maintain serum testosterone suppression to castrate levels (<= 50 ng/dL [1.7 nmol/L]) in men with androgen-sensitive advanced prostate cancer.Secondary:• To evaluate the time…